License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2015		2014		2015		2014
AstraZeneca AB	MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119)	$	40,000	$	105,000	$	130,000	$	105,001
Roche	PEGASYS® and MIRCERA®		3,212		3,200		9,619		9,614
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		357		793		1,562		3,939
Baxalta Incorporated	BAX 855 (Hemophilia)		409		9,096		607		10,103
Other			1,247		1,217		3,885		14,015
License, collaboration, and other revenue		$	46,475	$	120,556	$	149,423	$	146,422